

Clatterbridge Road Bebington Wirral CH63 4JY

Tel: 0151 556 5000 Web: www.clatterbridgecc.nhs.uk

Date: 26 April 2022

Re: Freedom of Information Request

Ref: 99-2022

Thank you for your email dated the 29/03/2022, requesting information treatment of uterine cancer at Clatterbridge

The information that you require is as follows:

What treatment do you give for uterine serous cancer - all lines of treatment including named chemo drugs?

Additionally if chemo had to be stopped, what further treatment would you give?

We follow the BGCS guidelines, treatment would depend on the stage of cancer. Adjuvant therapy would be offered postoperatively for early stage disease, with local practice changing to discuss chemotherapy (carboplatin (AUC5) /paclitaxel )in any patient with FIGO stage 1A (with muscle invasion) to stage 3C1. Patients would also be offered external beam radiotherapy and/or brachytherapy depending on the stage of the disease and patient factors.

For patients presenting with more advanced disease or metastatic, our current standard of care is to offer carboplatin (AUC5)/paclitaxel but we would also offer referral to The Christie in Manchester for consideration of trials as we don't have any first-line trials available at present.

Second-line treatment would depend on the patient's initial response. If they had a good response and had a gap of at least 6 months following progression we would consider rechallenging with carboplatin/paclitaxel. If they didn't respond to first line treatment or progressed more rapidly we would offer referral to the Christie for assessment for clinical trials as we don't have any trials open at present. We would also consider radiotherapy or rarely surgery for symptomatic control if appropriate.

We also assess patient's MMR status and if they are MMR deficient we would offer treatment with immunotherapy. This was previously nivolomab (Covid rules

Version: 1.0 Ref: ECGMFOIRE on CDF) and is now Dorstarlimab (although this is only available in the second-line setting.)

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

https://www.surveymonkey.co.uk/r/H39RFMM

Kind Regards,

The Information Governance Team Contact Email: ccf-tr.foi@nhs.net

Version: 1.0 Ref: ECGMFOIRE